The Elias Tillandz prize 2024 was awarded to an outstanding research article which offers a possible explanation as to why higher breast density and older age increase the risk of breast cancer. The Prize was awarded to the researchers at the BioCity symposium on Thursday, 29 August 2024.
A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the bloodstream of breast cancer patients.
Treatment outcomes for breast cancer have become better over the years, but proportion of breast cancers still recur even after long periods without signs of cancer remaining dormant in the body. Finnish cancer researchers discovered a mechanism that wakes up these dormant breast cancer cells and demonstrated that preventing the mechanism can significantly improve treatment outcomes in experimental models.
Researchers at the University of Turku in Finland have found a new function for an existing protein. They discovered that TIMP-1, a protein traditionally known to prevent damage to the body's cells and tissues, plays a critical role in the immune system's defence against cancer. The findings of the study could improve the effectiveness of current cancer immunotherapies.
Top-level skin cancer research acknowledging the individuality of cancer is conducted in Turku. In the studies, the characteristics of cancer are examined at the level of tracers and molecules. This opens up the opportunity to tailor the most suitable treatment for each patient. The studies are rewarding for both the researchers and the research subjects. At best, patients with advanced skin cancer benefit from the new medicinal products used in trials long before these products are in commercial use.
University of Turku Professors Johanna Ivaska and Lauri Nummenmaa have received significant research funding from the European Research Council ERC. Ivaska received funding for a project that aims to discover how the biological limits of a healthy body influence cancer progression. Nummenmaa’s project examines the link between a person’s negative emotions and their physical well-being.
Researchers at the University of Turku have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumour in cancer patients who do not respond to any other current therapies.
Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin, is the most common form of metastatic skin cancer. The incidence of cSCC is increasing worldwide with millions of new cases diagnosed each year. The prognosis of metastatic cSCC is poor as there are currently no effective targeted treatments available. New study conducted at the University of Turku, Finland, shows that plixorafenib, a new drug developed for treating melanoma and lung cancer, can also stop the progression of cutaneous squamous cell carcinoma.
This year, the Elias Tillandz Prize was awarded to two outstanding research articles, which involved a mechanism related to the migration of cancer cells and a new analysis of a grave dating back to the early Middle Ages. The Prize was awarded to the researchers at the BioCity symposium on Thursday, 24 August 2023.
Researchers have found a possible explanation as to why higher breast density and older age increase the risk of breast cancer.